2 active not recruiting, 2 recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 2, Recruiting 2 |
Follow volrustomig: new trials by email Literature Review of volrustomig trials Research Report on volrustomig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy volrustomig - Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Recruiting | AstraZeneca | 1145 | 2023-12-14 | 2026-09-30 |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma Volrustomig, Pemetrexed, Carboplatin - Unresectable Pleural Mesothelioma | Phase 3 | Active not recruiting | AstraZeneca | 863 | 2023-11-09 | 2026-10-23 |
| A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. Volrustomig, Pembrolizumab, Carboplatin - Metastatic Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | AstraZeneca | 895 | 2023-10-24 | 2026-10-09 |
| Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) Volrustomig, Placebo - Locally Advanced Cervical Cancer | Phase 3 | Recruiting | AstraZeneca | 800 | 2023-09-22 | 2026-11-10 |
Carcinoma, Non-Small-Cell Lung (1) · Mesothelioma (1) · Mesothelioma, Malignant (1)
AstraZeneca (4)
Brazil (4) · Canada (4) · China (4) · Germany (4) · Italy (4) · Japan (4) · Poland (4) · South Korea (4) · Spain (4) · Taiwan (4) · Turkey (Türkiye) (4) · United States (4) · Belgium (3) · France (3) · India (3)
Arnaud Scherpereel, MD (1) · Lisa Licitra, MD (1) · Marjorie G Zauderer, MD (1) · Robert Haddad, MD (1)
2023 (3)